Foreword
========

Antibiotics are the legacy of medicine; however, their competence is severely exposed to the evolution of the resistance. Since the discovery of antibiotics, the resistance has been detected and documented as an emerging threat; at present, almost all the first-generation antibiotics are ineffective. Basically, the main concern is the use of antibiotics as they not only stop the infections but also are associated with the evolution and emergence of the resistance, which clearly oppose the continuing use of antibiotics.[@b1-idr-11-1903] The inappropriate use of antibiotics including self-medication and the overprescribed antibiotic therapy especially in outpatient departments for nonbacterial respiratory tract infections are the most important factors that have contributed to the menace of antibiotic resistance.[@b2-idr-11-1903],[@b3-idr-11-1903]

Up till now, this crisis has been managed by discovering the new classes of antibiotics and continued alterations in existing compounds.[@b1-idr-11-1903] It is generally believed that the controlled use of specific antibiotics may nullify the advantage of selection and restore the general antibiotic sensitivity with the passage of time; on the other hand, years of practice and experience have revealed that antibiotic resistance is not easy to handle. Additionally, same is the case for the antibiotics that are given with various compounds that restrict the precise resistance mechanism; this line of action helped in enhancing and expanding the antibiotics spectrum. Owing to these problems, we need to develop novel ways that may stop the evolution of antibiotic resistance, turn the resistant bacterial population into the susceptible once again, or completely invert the selection of antibiotic resistance.[@b1-idr-11-1903],[@b4-idr-11-1903]

Advancements
============

Recently, it has been found that there are certain means that may be used to reverse the evolution of antibiotic resistance and they may also be helpful to invert the selective advantage of resistant bacterial strains. However, the single-drug therapy approach always facilitates bacteria to have the selective advantage to antibiotic resistance; combined antibiotics may stop the growth of bacteria and disfavor the resistance to the single drug.[@b1-idr-11-1903],[@b5-idr-11-1903],[@b6-idr-11-1903] Techniques have been developed that influence the specific physiological and evolutionary interactions between antibiotics, which as a result directly confer a disadvantage to resistant bacteria. First, if an antibiotic partly represses the efficacy of another, resistance to the first antibiotic would remove its protection to second compounds, which pose a disadvantage to resistant strains. Second, mutations associated with antibiotic resistance may be countered if these drugs produce a synergistic effect between antibiotics and other compounds.[@b5-idr-11-1903]

Modern technical advancements have permitted comprehensive systematic endeavors to find out the drug interfaces and their basic mechanisms. There are various studies that have revealed the antagonistic, synergistic, and suppressive effects between combinations of two antibiotics.[@b7-idr-11-1903],[@b8-idr-11-1903] Moreover, interactions between compounds with slight or no antibacterial activity and antibiotics are also shown. Study of pairwise interactions among different drugs has displayed that drugs having a similar mechanism of action contain an approximately analogous pattern of interaction proposing that drug interaction works via basic cell physiology and not via chemical interactions of these compounds directly.[@b9-idr-11-1903]--[@b11-idr-11-1903] Though, in case of a number of drugs, the exact mode of interaction of drug combinations is still undefined, modern studies have explained the phenomenon behind various interactions: sudden inhibition of various steps in the pathway produces a synergistic effect between sulfa drugs and trimethoprim.[@b12-idr-11-1903] It has been found that the nonoptimal gene regulation steers the suppressive interactions between fluoroquinolones and tetracyclines.[@b11-idr-11-1903] Moreover, mutations in ATP synthesis and polysaccharide reform a range of interactions among antibiotic combinations.[@b13-idr-11-1903] The recent studies have targeted the SOS response as a promising target to develop therapeutics that may help to decrease the emergence of antibiotic resistance. In future, targeting the SOS response can develop as a potential adjuvant strategy to revive our existing antibiotic collection; however, the molecular targets and related antimicrobial agents for such therapy are not much clear.[@b14-idr-11-1903]

Finally, there may be a compromise among resistances to various antibiotics; for example, resistance against one compound creates collateral sensitivity to other compound or to an antibiotic, which has resistance-mediated toxicity. Rapid mutation or acquired genes, which confer resistance against certain drugs, may enhance or reduce the resistance to the other antibiotic.[@b5-idr-11-1903] All these negative and positive interactions among the drugs are known as collateral sensitivity and cross-resistance, respectively. In case of resistance caused by spontaneous mutations, these interactions have been studied, which showed the presence of both collateral sensitivity and cross-resistance among various antibiotic pairs. This mechanism is not exclusive for antibiotics and bacteria; it also has been observed in HIV therapeutics, malaria, cancer therapeutics, and in various plants with resistance to different pesticides.[@b5-idr-11-1903],[@b6-idr-11-1903],[@b15-idr-11-1903] Significantly, in contrast to physiological interactions, combination therapy is not required in case of cross-resistance; however, it may be an evolutionary response to an antibiotic. In recent studies, it has been observed that with some exceptions, cross-resistance is found to be positive. Aminoglycosides are associated with negative cross-resistance due to modified proton motive force linked with antibiotic resistance.[@b6-idr-11-1903],[@b15-idr-11-1903] These methodologies may be employed to reverse the selection advantage of resistant bacterial strains, which are competing with sensitive strains and may possibly reduce the rate of the resistance evolution, or it may lead the resistant bacteria toward the antibiotic sensitivity once again.

Concerns
========

Considerable obstacles persist for the application of inversion therapeutic strategies in clinical settings. Antibiotic therapy choices should be made professionally, while the diagnosis of clinical infection may span over days despite the cutting-edge technologies. Additionally, the ideal choice of the therapeutic approaches is associated with bacterial genetics and their mechanisms of antibiotic resistance. Hence, clinical application of inversion therapeutic strategies would require rapid and novel diagnostic tools, which may detect the future evolutionary potential of a bacterium toward antibiotic resistance in addition to its existing resistance. These genetic diagnostic tools may also be helpful to update the therapeutics, the level of resistance to particular antimicrobial agents and the pathways that are used by these pathogens for resistance, and the discovery of novel mechanisms of resistance. Furthermore, in vitro data on selection inversion need to be validated through in vivo studies. Various approaches, which depend on combination therapy, are even more complex by pharmacokinetics that could differ across antibiotics. In addition to that, a specific drug interaction may alter in various genetic and environment settings or with the time as bacteria evolve.

In conclusion, the implementation of such approaches needs a cautious ethical equilibrium between treating the patients and decreasing the antibiotic resistance in the community. Eventually, fighting antibiotic resistance would demand a range of plans, which should be able to anticipate the bacterial evolution and become accustomed to both remedy and evade resistance.
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